Zepp Health’s 70 percent stock slide in 2026 puts Q1 earnings in focus

Zepp Health heads into its next earnings update with a strange setup. The Amazfit business looks healthier than it has for a while, but the stock has fallen sharply in 2026 after a huge run last year.

The company will report its first quarter 2026 results after the market closes on Monday, June 8. That gives investors a fresh chance to decide whether last year’s recovery was the start of something more durable, or simply a sharp bounce from a very low base.

The company’s shares closed at $7.60 on June 2. That is down heavily from where the stock started the year, with the chart showing a fall of more than 70 percent so far in 2026!

Zoom out further and the picture becomes even stranger. The five-year chart shows a long collapse after the 2021 highs, a quiet period near the bottom, then a sharp 2025 spike before the latest drop.

A big bounce needed follow-through

The easiest way to understand the recent weakness is to start with the size of the previous move. Zepp Health was a deeply beaten-down stock before 2025. The company had dealt with falling revenue, losses, a weaker Xiaomi-linked legacy business and a share price low enough to trigger NYSE minimum price concerns in 2024.

When a stock climbs from very depressed levels, the percentage gains can look dramatic very quickly. Zepp Health’s 2025 move appears to have come from investors reassessing the company after signs of a proper Amazfit-led recovery. Revenue growth returned, margins looked stronger and the brand was clearly pushing harder into premium sports, outdoor and recovery-focused devices.

The problem is that markets rarely reward the same recovery twice. Once the stock had already moved sharply higher, investors needed fresh evidence. That means Q1 2026 now carries more weight than a normal quarterly update. The company does not just need to show that 2025 improved. It needs to show that the improvement can continue.

The business story is better than the chart

The share price decline looks rough, but it does not mean the underlying business has fallen apart. Zepp Health’s full-year 2025 results were a clear improvement from the previous year. Revenue reached $258.9 million, up 41.8 percent year-on-year, while Amazfit-branded product revenue grew strongly and accounted for all of the company’s revenue.

Margins also looked healthier. Full-year gross margin came in at 38.3 percent, and the fourth quarter reached just above 40 percent. Zepp Health has spent the past couple of years trying to reshape itself around Amazfit rather than relying on older business lines, and the 2025 numbers suggest that shift has started to work.

But there is a catch. Zepp Health still reported a net loss for 2025, even though that loss narrowed compared with 2024. Investors can tolerate losses when growth is strong and the path to profitability looks clear. They become less patient when a stock has already run hard and the next quarter has not yet confirmed the trend.

That is probably one reason for the current pressure. The stock market is not saying the Amazfit story has failed. It may simply be asking for more proof.

Product momentum needs to show up in numbers

From a wearable-tech point of view, Zepp Health has been busy. The Amazfit range has become more focused, with stronger emphasis on sports watches, outdoor models, recovery features and software updates. Devices such as Balance, T-Rex and Cheetah models give the brand a clearer identity than it had during the cheaper fitness band years.

There is also the Helio line, which points to a broader recovery and training ecosystem rather than just another watch release. That is where the company could become more interesting if it can link hardware, readiness, sleep, training load and coaching in a way that feels useful to everyday athletes.

What to watch on June 8

Investors will want product activity to translate into revenue, margin and guidance. A busy launch calendar does not automatically create a stronger business. Zepp Health needs to show that its premium positioning can hold, that demand has not cooled after the 2025 rebound and that marketing spend does not swallow the margin gains.

The headline revenue numbers on June 8 will matter, but the details will tell the better story. Investors will look closely at Amazfit-branded product sales, gross margin and operating expenses. They will also watch guidance for the next quarter. Product commentary could be just as important.